Evidence mapPaperPMID 33537828Full record

ArticleMolecular medicine reports2021

MicroRNA‑186‑5p downregulation inhibits osteoarthritis development by targeting MAPK1.

Qing Li, Mingjie Wu, Guofang Fang, Kuangwen Li, Wengang Cui, Liang Li, Xia Li, Junsheng Wang, Yanhong Cang

Open access · bronzeAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qing LiDepartment of Orthopedics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518101, P.R. China.
Mingjie WuDepartment of Orthopedics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518101, P.R. China.
Guofang FangDepartment of Orthopedics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518101, P.R. China.
Kuangwen LiDepartment of Orthopedics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518101, P.R. China.
Wengang CuiDepartment of Orthopedics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518101, P.R. China.
Liang LiDepartment of Orthopedics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518101, P.R. China.
Xia LiDepartment of Orthopedics, The Second People's Hospital of Huai'an, Huai'an, Jiangsu 223002, P.R. China.
Junsheng WangDepartment of Orthopedics, The Second People's Hospital of Huai'an, Huai'an, Jiangsu 223002, P.R. China.
Yanhong CangDepartment of Orthopedics, The Second People's Hospital of Huai'an, Huai'an, Jiangsu 223002, P.R. China.
Southern Medical University Shenzhen Hospital · CNXuzhou Medical College · CNSecond People’s Hospital of Huai’an · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a chronic degenerative joint disease, the characteristics of osteoarthritis (OA) are degeneration of articular cartilage, subchondral bone sclerosis and bone hyperplasia. It has been reported that microRNA (miR)‑186‑5p serves a key role in the development of various tumors, such as osteosarcoma, non‑small‑cell lung cancer cells, glioma and colorectal cancer. The present study aimed to investigate the effect of miR‑186‑5p in OA. Different concentrations of IL‑1β were used to treat the human chondrocyte cell line CHON‑001 to simulate inflammation, and CHON‑001 cell injury was assessed by detecting cell viability, apoptosis, caspase-3 activity and the levels of TNF‑α, IL‑8 and IL‑6. Subsequently, reverse transcription‑quantitative PCR was performed to measure miR‑186‑5p expression. The results demonstrated that following IL‑1β treatment, CHON‑001 cell viability was suppressed, apoptosis was promoted, the caspase-3 activity was significantly enhanced and the release of TNF‑α, IL‑8 and IL‑6 was increased. In addition, IL‑1β treatment significantly upregulated miR‑186‑5p expression in CHON‑001 cells. It was also identified that MAPK1 was a target gene of miR‑186‑5p, and was negatively regulated by miR‑186‑5p. miR‑186 inhibitor and MAPK1‑small interfering RNA (siRNA) were transfected into CHON‑001 cells to investigate the effect of miR‑186‑5p on CHON‑001 cell injury induced by IL‑1β. The results demonstrated that miR‑186 inhibitor suppressed the effects of IL‑1β on CHON‑001 cells, and these effects were reversed by MAPK1‑siRNA. In conclusion, the present results indicated that miR‑186‑5p could attenuate IL‑1β‑induced chondrocyte inflammation damage by increasing MAPK1 expression, suggesting that miR‑186‑5p may be used as a potential therapeutic target for OA.

Indexed as

Down-RegulationCell LineChondrocytesCytokinesHumansMicroRNAsMitogen-Activated Protein Kinase 1OsteoarthritisCytokinesMAPK1 protein, humanMicroRNAsMIRN186 microRNA, humanMitogen-Activated Protein Kinase 1chondrocytesinflammatory injurymicroRNA‑186‑5posteoarthritis

Identifiers

PMID33537828
PMCPMC7893783
OpenAlexW3126285374

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.